Abstract
An overview of vortioxetine
Schatzberg AF, Blier P, Culpepper L, Jain R, Papakostas GI, Thase ME
J Clin Psychiatry. 2014; 75(12):1411-8.
Abstract
Six clinicians provide an overview of the serotonergic antidepressant vortioxetine, which was recently approved for the treatment of major depressive disorder in adults. They discuss the pharmacologic profile and receptor-mediated effects of vortioxetine in relation to potential outcomes. Additionally, they summarize the clinical trials, which demonstrate vortioxetine's efficacy, and discuss findings related to safety and tolerability that have high relevance to patient compliance.